Ocular Therapeutix (OCUL) Total Non-Current Liabilities (2013 - 2026)

Ocular Therapeutix's Total Non-Current Liabilities history runs 11 years deep, the most recent figure standing at $150.0 million for Q1 2026.

• In Q1 2026, Total Non-Current Liabilities rose 7.29% year-over-year to $150.0 million; the TTM figure through Mar 2026 stood at $150.0 million (up 7.29% YoY), while the FY2025 annual figure was $139.8 million, down 1.83% from the prior year.
• Total Non-Current Liabilities was $150.0 million for Q1 2026 at Ocular Therapeutix, up from $139.8 million in the prior quarter.
• In the past five years, Total Non-Current Liabilities ranged from a high of $150.0 million in Q1 2026 to a low of $94.6 million in Q1 2022.
• Historically, Total Non-Current Liabilities has averaged $124.1 million across 5 years, with a median of $130.9 million in 2023.
• The sharpest annual moves came in 2023 and 2024: Total Non-Current Liabilities jumped 42.07% in 2023, then retreated 3.43% in 2024.
• A 5-year view of Total Non-Current Liabilities shows it stood at $107.6 million in 2022, then increased by 21.74% to $130.9 million in 2023, then rose by 8.79% to $142.4 million in 2024, then slipped by 1.83% to $139.8 million in 2025, then advanced by 7.3% to $150.0 million in 2026.
• The last three Total Non-Current Liabilities figures came in at $150.0 million (Q1 2026), $139.8 million (Q4 2025), and $137.7 million (Q3 2025), per Business Quant data.